News
Dubai Healthcare City expands longevity offering

Dubai Healthcare City has expanded its longevity and pharmaceutical services at the World Health Expo Dubai 2026.
The expansion brings together what the free zone describes as a new longevity-led preventive care programme and an AI-driven tele-compounding pharmacy platform.
The additions expand the range of personalised care pathways available within the ecosystem, with a focus on long-term wellbeing, clinical governance and precision medicine.
Rashed Ahmed Alawadhi, director of property management at Dubai Healthcare City Authority, said: “Our role is to ensure that the physical and operational environment supports the next generation of healthcare delivery.
“The expansion of longevity-focused services alongside advanced pharmaceutical models such as AI-driven tele-compounding reflects how our infrastructure is evolving to meet the needs of specialised, precision-led care.
“By providing fit-for-purpose facilities and integrated developments, we enable healthcare providers to operate efficiently, scale responsibly, and deliver high-quality outcomes within the DHCC ecosystem.”
Proto Clinic is strengthening Dubai Healthcare City’s preventive care offering through the introduction of what it describes as a personalised, science-led programme within the ecosystem.
Designed to enhance healthspan, the period of life spent in good health, the programme integrates advanced diagnostics, genomics, lifestyle medicine and continuous monitoring to deliver individualised pathways.
Wissam Adada, founder and chairman of Proto Clinic, said: “Longevity medicine requires a shift from reactive treatment to a clinically grounded, preventive approach tailored to each individual.
“At Proto Clinic, we combine advanced diagnostics, genomics and lifestyle medicine to deliver personalised longevity pathways that improve healthspan and long-term wellbeing, guided by a decade of clinical practice and multidisciplinary expertise.
“Operating within DHCC’s ecosystem allows us to deliver the programme within a regulated, innovation-ready environment that supports high standards of clinical care.”
Dubai Healthcare City has also introduced The Formula, which it describes as the Middle East’s first AI-driven tele-compounding pharmacy platform, developed to enhance access to precision therapies. Compounding refers to the preparation of customised medicines for individual patients.
The Formula brings together clinical intelligence, pharmaceutical-grade compounding and AI decision-support in a single digital workflow.
Patients can access custom-compounded medications with personalised dosages, delivered through an end-to-end pathway that includes digital consultation, AI-augmented clinical assessment, bespoke formulation and regulated fulfilment.
The platform supports clinicians through decision-support tools, ensuring medical judgement remains central while enabling personalised therapies to be delivered.
Ameera Youssef, chief executive of Acorn Research and co-founder of The Formula, commented: “The launch of ‘The Formula’ within DHCC marks a significant milestone for personalised pharmaceutical care in the region.
“By combining AI-supported clinical insight with regulated compounding pharmacy workflows, we are redefining how customised medicines are prescribed, prepared and monitored, while ensuring patient safety and clinical governance remain central.”
Dubai Healthcare City was established in 2002 and is governed by Dubai Healthcare City Authority, a Dubai Government entity.
News
Gut-friendly foods may damage heart, charity warns
News
Diabetes patients face increased risk of undiagnosed heart failure

People with diabetes may have undiagnosed heart failure that could be detected by a simple screening blood test, research suggests.
The TARTAN-HF trial found that one in four patients with diabetes who had at least one other risk factor for heart failure had undiagnosed heart failure detected through screening with a blood test and ultrasound scanning of the heart.
Experts said the findings show the extent of unrecognised heart failure in people with diabetes, and how the condition can be detected using a widely available blood test called NT-proBNP, which measures how much strain the heart is under.
They suggest a heart failure screening programme for diabetics could improve diagnosis rates, lead to earlier treatment and potentially reduce the risk of hospitalisation and death.
The study, involving 700 patients, was led by the University of Glasgow in collaboration with AstraZeneca, Roche Diagnostics, Us2.ai, NHS Greater Glasgow and Clyde and NHS Lanarkshire.
Dr Kieran Docherty, clinical senior lecturer at the University of Glasgow’s School of Cardiovascular and Metabolic Health, said: “Our results from the landmark TARTAN-HF trial identified heart failure in a large proportion of people living with diabetes, emphasising the need for a heart failure screening strategy in this group of patients.
“We know that many of the symptoms and signs of heart failure are non-specific, and may go unrecognised as potentially being due to heart failure for a long time.
“The strategy used in our trial is simple and easy to implement in clinical practice, and will aid in the early identification of heart failure in people with diabetes, and facilitate the initiation of medications that we know improve outcomes in patients with heart failure.”
The study, which began more than three years ago, involved more than 700 people with diabetes from the two health board areas who had at least one other risk factor for heart failure.
They were randomly assigned either to receive heart failure screening or to continue with their usual care.
Researchers found screening uncovered a large number of previously unrecognised cases of heart failure. Around one in four, or 24.9 per cent, of those screened were found to have the condition within six months, compared with 1 per cent in the group continuing their usual care.
The study, involving patients with type 1 and type 2 diabetes, found almost all of the participants found to have heart failure had preserved ejection fraction, which can be difficult to detect without dedicated testing.
The findings of the TARTAN-HF trial were presented at the American College of Cardiology conference taking place from 28 to 30 March in New Orleans in the US.
Dr Edward Piper, medical director at AstraZeneca UK, said: “Delayed diagnosis and treatment of heart failure in people with type 2 diabetes contributes to poor long-term outcomes. TARTAN-HF demonstrates that targeted, risk-based screening can identify previously undiagnosed heart failure in approximately one in four high-risk patients with diabetes, enabling earlier intervention with guideline-directed therapy.”
Dr Christian Simon, head of global medical affairs at Roche Diagnostics, said: “We are proud to have supported the landmark TARTAN-HF trial. These findings demonstrate the transformative power of early, accessible diagnostics like the NT-proBNP blood test.
“By identifying unrecognised heart failure in people with diabetes, we enable clinicians to initiate appropriate treatments sooner, ultimately improving patient outcomes and lives.”
News
UK government announces £6.3m fund to boost men’s health

The UK has launched a £6.3m men’s health fund to back local projects aimed at helping men and boys live longer, healthier lives.
The Men’s Health Community Fund is a partnership between the Department of Health and Social Care, Movember and People’s Health Trust.
The government is contributing £3m, while the two charities are more than doubling that to take the total to £6.3m.
Grants will support community projects reaching underserved men and boys aged 16 and over, particularly in the most disadvantaged areas and at key points in their lives such as becoming a father, losing a job or retiring.
Projects could include support for new fathers, activities for men facing loneliness and social isolation, services to help young men engage with the health system, and support for men in work, out of work and moving into retirement.
The programme will bring together voluntary, community and social enterprise organisations to test new ways of reaching men who are least likely to use traditional health services.
An evaluation funded through the National Institute for Health and Care Research will assess what works and help inform future policy and delivery.
Health and social care secretary Wes Streeting said: “Too many men across the country are living shorter, less healthy lives, particularly those in our most disadvantaged communities.
“This new partnership will help men get the support they need in the places they feel most comfortable, their communities, among people they trust.
“By working with expert charities and local organisations, we can reach the men who are too often missed by traditional services and help them take better care of their mental and physical health.”
“It is a key step in delivering our first ever Men’s Health Strategy and driving forward our ambition to halve the gap in healthy life expectancy between the richest and poorest areas.”
The Men’s Health Strategy sets out plans to tackle the physical and mental health challenges men and boys face.
Men can be less likely to seek help and more likely to suffer in silence, while higher rates of smoking, drinking, gambling and drug use are damaging men’s health and affecting families, workplaces and communities.
The government is also investing £3.6m over the next three years in suicide prevention projects for middle-aged men in local communities across areas of England where men are most at risk, many of which are also among the most deprived. Suicide is one of the biggest killers of men under 50, and three-quarters of all suicides are men.
The projects will aim to break down barriers middle-aged men face in seeking support, including stigma around asking for help and a lack of awareness of what is available and how to access it.
They will be co-designed with experts and men with lived experience of mental health crises and suicidal thoughts.








